Skip to main content
Future Journal of Pharmaceutical Sciences

Table 5 Robustness study of the developed UHPLC method for quantification of SOF, LDV and PAR

From: Rapid and validated UHPLC method for simultaneous determination of sofosbuvir, ledipasvir and paracetamol as commonly repurposed drugs for COVID-19 treatment: application in spiked human plasma

UHPLC parameters

SOF

LDV

PAR

%RSD of peak areas

%RSD of peak areas

%RSD of peak areas

Flow rate a

0.645

1.149

0.529

Mobile phase ratiob

0.546

0.563

0.793

Temperaturec

0.537

0.581

0.264

  1. a0.35, 0.45 ml min−1 for SOF, LDV and PAR
  2. bRatio of mobile phase (40/60 v/v), (44/56 v/v) (acetonitrile/0.1 opa v/v)
  3. cTemperature (30 ± 2 °C)
Back to article page